Assessment of swallowability and palatability of oral dosage forms in children: Report from an M-CERSI pediatric formulation workshop.

Autor: Ternik R; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: ternik_robert_l@lilly.com., Liu F; Department of Pharmacy, Pharmacology and Postgraduate Medicine, University of Hertfordshire, College Lane, Hatfield AL10 9AB, UK. Electronic address: f.liu3@herts.ac.uk., Bartlett JA; Pfizer Inc., Worldwide Research and Development, Pharmaceutical Sciences, Drug Product Design, Groton, CT 06340, USA., Khong YM; Abbvie Inc., 1 N Waukegan Rd, North Chicago, IL 60064, USA., Thiam Tan DC; Abbvie Inc., 1 N Waukegan Rd, North Chicago, IL 60064, USA., Dixit T; Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL 60015, USA., Wang S; Norwegian Medicines Agency, Strømsveien 96, 0663 Oslo, Norway., Galella EA; Bristol-Myers Squibb, New Brunswick, NJ 08903, USA., Gao Z; Bristol-Myers Squibb, New Brunswick, NJ 08903, USA., Klein S; Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Ernst Moritz Arndt University Greifswald, Felix-Hausdorff-Strasse 3, 17489 Greifswald, Germany.

Publikováno v: International journal of pharmaceutics [Int J Pharm] 2018 Feb 05; Vol. 536 (2), pp. 570-581. Date of Electronic Publication: 2017 Aug 24.